Dyax, the Cambridge, MA-based drug developer, said today that Gustav Christensen will replace co-founder Henry Blair as president and CEO on Jan. 1. Christensen joined the company as chief business officer in April 2007. Blair, who co-founded the company in 1989, plans to retire as CEO but remain chairman of the board at Dyax.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
